Magazine Article | November 1, 2023

The Power Couple Behind Krystal Biotech

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Last May, Pittsburgh-based Krystal Biotech achieved a litany of firsts with the FDA approval of Vyjuvek, the first approval of a topical and redosable gene therapy; the first approval of a gene therapy using herpes simplex virus (HSV-1) as a vector; the first approved drug for the treatment of wounds caused by dystrophic epidermolysis bullosa (DEB), a rare skin disease; and Krystal Biotech’s first approved product. Surmounting the challenges and complexity inherent to those achievements — navigating uncharted regulatory territory and building an internal quality testing and manufacturing capability from scratch, for example — required deft leadership on numerous fronts.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader